New immunotherapy combo aims to tackle tough lung cancer
NCT ID NCT07009457
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called SHR-1316, given as a shot under the skin, together with standard chemotherapy (carboplatin and etoposide) in people with extensive-stage small cell lung cancer who have not had prior treatment. The study looks at how the drug moves through the body, its safety, and whether it helps shrink tumors. About 24 participants will take part to gather initial information on dosing and effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1316 (an experimental immunotherapy) combined with carboplatin and etoposide (chemotherapy)
What this could lead to
If successful, this could lead to a new first-line treatment option for extensive-stage small cell lung cancer, potentially improving tumor control and survival.
What could go wrong
This is an early Phase 1 trial with only 24 participants, so safety and effectiveness are not yet established. The combination may cause significant side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WIDESPREAD SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330200, China